Yebio Bioengineering (China)

Qingdao Yebio Bioengineering Co., Ltd. (Yebio Bioengineering) is a Chinese high-technology enterprise founded in 1999 and headquartered in Qingdao, Shandong Province. The company specializes in veterinary biological products — vaccines, diagnostics and treatments — for poultry, waterfowl, livestock and companion animals. Its activities span research and development, manufacturing, sales, technical service and international trade, making it one of China's integrated animal-health players. Yebio's product portfolio is organized around four animal categories. For poultry it offers recombinant avian influenza inactivated vaccines (H5+H7 tetravalent), combined Newcastle disease / avian influenza (H9) / avian adenovirus vaccines, and live vaccines such as the Newcastle disease–infectious bronchitis bivalent and fowl pox vaccine. For waterfowl it produces vaccines against duck Tembusu virus, duck viral hepatitis, Muscovy duck parvovirus, gosling plague and duck infectious serositis. For livestock it markets genetically engineered subunit vaccines against classical swine fever and porcine circovirus type 2, a highly pathogenic porcine reproductive and respiratory syndrome live vaccine, and other swine vaccines. For companion animals it offers a rabies inactivated vaccine. According to the company, it ranks third among global poultry vaccine enterprises and eighteenth among global animal-health companies, citing the 2021 International Poultry "Top 50 Global Animal Health Companies" list. Yebio describes itself as a leading global animal-health enterprise and emphasizes "focused, dedicated, professional" operations, precision R&D and smart manufacturing. Yebio has invested heavily in intelligent manufacturing. It developed an intelligent chicken-embryo candling system using computer vision and machine learning, along with automatic egg inoculation and harvesting machines and an automated low-temperature stereoscopic warehouse. In 2021 its Qingdao animal vaccine smart-manufacturing project passed expert acceptance by China's Ministry of Industry and Information Technology. The company also operates a high-level pathogen laboratory (ABSL-3/BSL-3) that passed CNAS review and activity approval in early 2024, and co-built the National Key Laboratory of Veterinary Public Health Safety with China Agricultural University. Yebio's technical service department traces its origins to 1990 at the former Animal Quarantine Institute of the Ministry of Agriculture (now the China Animal Health and Epidemiology Center). The company runs the "Yebio Xiao e" mini-program covering disease warning, intelligent diagnosis, testing services, expert consultation and a technical encyclopedia. Yebio holds honors including National Science and Technology Progress Award, National Technology Invention Award, China Well-Known Trademark, and designations as a national agricultural industrialization key leading enterprise and a Qingdao biomedicine and medical device industry-chain lead enterprise.

Qingdao Yebio Bioengineering Co., Ltd. was founded in 1999 in Qingdao, Shandong Province, and was recognized as a Qingdao high-technology enterprise in its founding year. The company's technical service department traces its origins to 1990, when it was established within the Animal Quarantine Institute of the Ministry of Agriculture (now the China Animal Health and Epidemiology Center). The company's technology center also has roots in the 1996 poultry disease and biological products research offices of that institute, and was formally established as Yebio's technology center in 1999. In 2002, "Yebio Bio" received the Shandong Province animal husbandry (veterinary drug) top ten well-known brand enterprise certificate. In 2004, the company became a state-designated production and export enterprise for avian influenza vaccines. In 2006, it was recognized as a national-level enterprise research and development center. In 2007, the "Yebio" trademark was recognized as a Shandong Province Famous Trademark by the Shandong Administration for Industry and Commerce. In 2010, the company built out its swine vaccine system. The period 2011–2021 is described by the company as its "pioneering and leading" era. In 2012, it began developing genetically engineered vaccines and comprehensively adjusted its product structure. In 2013, it received the National Science and Technology Progress Award (second class) and the National Technology Invention Award (second class). In 2015, it was associated with the State Key Laboratory of Animal Genetic Engineering Vaccines, the National-Local Joint Engineering Research Center, and high-technology enterprise status. In 2018, it was approved for the "Made in China 2025" animal vaccine smart-manufacturing new-model application project. In 2019, the Yebio technical team released the GVP (Good Vaccination Practice) guide and operation videos to the industry as open-source, freely downloadable resources after more than a decade of work. In 2020, the second-generation intelligent chicken-embryo candling system successfully addressed a key industry technical challenge. In 2021, Qingdao Yebio's animal vaccine smart-manufacturing new model passed expert acceptance by the Ministry of Industry and Information Technology with high marks, and the Qingdao Yebio Immunology Technology Research Institute was established. From 2022 onward, the company describes its phase as one of "leapfrog breakthroughs," focusing on smart-manufacturing upgrades, new industrial clusters and resource integration. In early 2024, Yebio's high-level pathogen microbiology laboratory (ABSL-3, BSL-3) passed CNAS review and experimental activity approval, enabling rapid research on virulent and emerging animal infectious diseases. The company also co-built the National Key Laboratory of Veterinary Public Health Safety with China Agricultural University, focusing on animal-source bacterial resistance, emerging and re-emerging important animal pathogens, and animal-origin zoonoses.

• 2024

  High-level pathogen laboratory (ABSL-3, BSL-3) passed CNAS review and experimental activity approval.

• 2021

  Animal vaccine smart-manufacturing new model passed expert acceptance by the Ministry of Industry and Information Technology; Qingdao Yebio Immunology Technology Research Institute established.

• 2020

  Second-generation intelligent chicken-embryo candling system solved a key industry technical challenge.

• 2019

  Released the GVP guide and operation videos to the industry as open-source, freely downloadable resources.

• 2018

  Approved for the "Made in China 2025" animal vaccine smart-manufacturing new-model application project.

• 2015

  Associated with State Key Laboratory of Animal Genetic Engineering Vaccines, National-Local Joint Engineering Research Center, and high-technology enterprise status.

• 2013

  Received National Science and Technology Progress Award (second class) and National Technology Invention Award (second class).

• 2012

  Began developing genetically engineered vaccines and adjusted product structure.

• 2010

  Built out its swine vaccine system.

• 2007

  "Yebio" trademark recognized as a Shandong Province Famous Trademark.

• 2006

  Recognized as a national-level enterprise research and development center.

• 2004

  Became a state-designated production and export enterprise for avian influenza vaccines.

• 2002

  "Yebio Bio" received the Shandong Province animal husbandry (veterinary drug) top ten well-known brand enterprise certificate.

• 1999

  Yebio founded in Qingdao; recognized as a Qingdao high-technology enterprise.

Global animal-health leader focused on precision R&D and smart manufacturing of veterinary biological products.

• Recombinant avian influenza (H5+H7) tetravalent inactivated vaccine

• Newcastle disease / avian influenza (H9) / avian adenovirus trivalent inactivated vaccine

• Newcastle disease / infectious bronchitis / infectious bursal disease / viral arthritis quadrivalent inactivated vaccine

• Newcastle disease / infectious bronchitis bivalent live vaccine

• Fowl pox live vaccine

• Duck Tembusu virus live vaccine

• Duck viral hepatitis bivalent yolk antibody

• Muscovy duck parvovirus / gosling plague bivalent live vaccine

• Duck infectious serositis trivalent inactivated vaccine

• Classical swine fever genetically engineered subunit vaccine

• Porcine circovirus type 2 genetically engineered subunit vaccine

• Highly pathogenic porcine reproductive and respiratory syndrome live vaccine

• Pseudorabies live vaccine

• Swine erysipelas live vaccine

• Rabies inactivated vaccine (companion animals)

1. 1青岛易邦生物工程有限公司-易邦生物yebio.com
2. 2发展历程-易邦生物yebio.com
3. 3走进易邦-易邦生物yebio.com
4. 4公司荣誉-易邦生物yebio.com
5. 5Yebio Bioengineering (China) - Wikidatawikidata.org